Atorvastatin vs simvastatin. national chart of basic medicines of Ecuador

Abstract:

The purpose of this study was elaborate the form for inclusion of atorvastatin in the National Basic Medicines Chart of Ecuador to reduce the risk of adverse effects in patients with HIV at the Martín Icaza Hospital clinic. A pharmacovigilance study was con- ducted on 629 HIV patients who consumed ator-vastatin and simvastatin. The 76.42% of the patients with antiretroviral treatment were be-tween 20-45 years of age; 57.55% were males; 52.83% received treatment with nucleoside ana-log reverse transcriptase inhibitors + nucleo-side reverse transcriptase inhibitors; 30.89% consumed statins; 63 drug interactions were de-tected predominantly in the use of simvastatin; 78.30% presented adverse drug reactions; 100% of patients taking simvastatin had myalgias. Atorvastatin is the drug of choice for patients with HIV and hypercholesterolemia therefore, its inclusion in the National Basic Medicines Chart of Ecuador is required.

Año de publicación:

2018

Keywords:

• National chart of basic medicines
• statins
• adverse drug reactions
• Human immunodeficiency vi-rus

Fuente:

scopus